euraAPi
Active Solutions for Health
Introduction David Seignolle
Chief Executive Officer
H1 2025 Key Figures
€37.8m
60% dedicated to growth
Net Sales
Core EBITDA
€412.1m (8.2)%
Sanofi
€176.1m
-15.3%
Other Clients
€236.0m
-2.0%
€39.5m
Core EBITDA margin 9.6%
EBITDA
CAPEX
€5.0m
€39.3m exceptional items
H1 2025 key takeaways
Thorough execution of the FOCUS-27 plan
Resilience
Sales to SanofiAPIs sales affected by unfavorable comparison base and lower sales from Sevelamer
Strong performance of the CDMO activity driven by large-scale contracts in anti-infective and skin care
Sales to Other ClientsSolid growth in Opioids and unfavorable phasing in Vitamin B12 sales
Gradual ramp-up of recent CMO projects more than offset by the downsizing of pre-carve out contracts, ongoing derisking of the portfolio
Discipline
Reduced Personnel Costs
Sustained savings in external spendings
Tight management of Operating Working Capital Controlled and targeted CAPEX
Execution
Successful divestment of the Haverhill site to Particle Dynamics API discontinuation program progressing as planned Agreement on IPCEI signed with the French Government
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |